Brief: Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
27/10/2025 13:31
Oct 27 (Reuters) - Biomea Fusion Inc BMEA.O: BIOMEA FUSION ANNOUNCES FIRST PATIENT DOSED IN PHASE I STUDY OF BMF-650 A NEXT-GENERATION ORAL GLP-1 RECEPTOR AGONIST Source text: ID:nGNX8z1GCz Further company coverage: BMEA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes